Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation

Chuanfu QIN; Yali ZHAO; Lijuan LONG; Hua QIU

doi:10.3969/j.issn.1001-5256.2023.10.011

Volume 39 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(10): 2340-2347

PDF( 1118 KB)

Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation

DOI: 10.3969/j.issn.1001-5256.2023.10.011

1.
Department of Traditional Chinese Medicine，Guangxi Medical University Cancer Hospital，Nanning 530021，China
2.
The First Clinical Medical College of Guangxi Medical University，Nanning 530021，China

Research funding:

National Natural Science Foundation Project (81860889);

National Natural Science Foundation Project (81660827);

Guangxi Natural Science Foundation Project (2020GXNSFAA297113)

More Information

Corresponding author: QIU Hua，qiuhua8899@163.com （ORCID： 0000－0001－7297－7214）
Received Date: 2022-12-21
Published Date: 2023-10-30

Abstract

Abstract

Objective To investigate whether cytotoxic T lymphocyte （CTL）－derived exosomes can downregulate HBx expression and inhibit hepatic stellate cell （HSC） activation. Methods The supernatants of HepG2， HepGA14， and CTL cells were collected to extract exosomes， which were referred to as NC－exo， HBV－exo， and CTL－exo， respectively）. Transmission electron microscopy was used to observe their morphology， and Western Blot was used to measure the expression of the markers of exosomes CD63 and TSG101. NC－exo， HBV－exo， and CTL－exo labeled by BODIPY dye were mixed with HBV－exo at different ratios and were then co－cultured with HSC LX－2 （HSC－LX2）. A fluorescence microscope was used to observe whether exosomes could enter LX－2 cells， and an fluorescence microscope was used to observe cell morphological changes； quantitative real－time PCR （qPCR） was used to measure the expression of the activated biomarkers such as transforming growth factor－β1 （TGF－β1）， ɑ－smooth muscle actin （ɑ－SMA）， and collagen type I （Collagen I） in LX－2 cells. CTL－exo was added to the HepGA14 culture system； then qPCR was used to measure the mRNA expression level of HBV DNA， cccDNA， and HBx in exosomes in HepGA14 cells， and Western Blot was used to measure the protein expression level of HBx in exosomes. The t-test was used for comparison of normally distributed continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results The exosomes were all microcysts with a double－layer membrane structure and were circular or elliptical in shape， with the expression of the signature proteins CD63 and TSG101， and the vesicles had a diameter of 50－100 nm. The fluorescence microscope showed that exosomes could enter LX－2 cells， and HSC were enlarged with extended cell processes. The results of qPCR showed that there were significant differences in the expression levels of TGF－β1， ɑ－SMA， and Collagen I genes between the NC－exo， HBV－exo， NC－exo+HBV－exo， and Con groups （F=444.678， 417.144， and 571.508， all P<0.05）. After the intervention of HepGA14 cells with CTL－exo， qPCR results showed that compared with the control group， there were significant reductions in the expression levels of HBV DNA and cccDNA in HepGA14 cells （all P<0.05）， the relative mRNA expression level of HBx in exosomes （P<0.05）， and the protein expression level of HBx （P<0.05）. CTL－exo and HBV－exo were mixed at different ratios （2∶1， 5∶1， 10∶1） and were then used for the intervention of LX－2 cells， and qPCR results showed that the expression levels of TGF－β1， ɑ－SMA， and Collagen I genes in LX－2 cells gradually decreased with the increase in the ratio of CTL－exo between groups （P<0.05）. Conclusion CTL－exo can downregulate the protein expression of HBx in HBV－exo to inhibit HSC activation， suggesting that CTL－exo has an anti－hepatitis B liver fibrosis effect.
- Hepatic Fibrosis,
- T－Lymphocytes， Cytotoxic,
- Exosomes,
- Hepatic Stellate Cells,
- Hepatitis B Virus X Protein

FullText(HTML)

References(23)

References

[1]	LI T, YAN Y, WANG B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis[J]. Stem Cells Dev, 2013, 22( 6): 845－ 854. DOI: 10.1089/scd.2012.0395.
[2]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.
[3]	LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230－ 238. DOI: 10.2471/BLT.18.219469.
[4]	LIU JW, XIE J, LI TS. Specific T-lymphocyte response and clinical outcome of patients with hepatitis B virus infection[J]. Med J Peking Union Med Coll Hosp, 2012, 3( 3): 350－ 353. DOI: 10.3969/j.issn.1674－9081.2012.03.021. 刘佳文, 谢静, 李太生. 乙型肝炎病毒感染者特异性T淋巴细胞应答与临床转归[J]. 协和医学杂志, 2012, 3( 3): 350－ 353. DOI: 10.3969/j.issn.1674－9081.2012.03.021.
[5]	MA S, CHEN X, TAN Q, et al. An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV－specific CTL response by upregulating autophagy in T cells[J]. Cell Cycle, 2018, 17( 10): 1220－ 1234. DOI: 10.1080/15384101.2018.1471312.
[6]	CHENG ST, REN JH, CAI XF, et al. HBx－elevated SIRT2 promotes HBV replication and hepatocarcinogenesis[J]. Biochem Biophys Res Commun, 2018, 496( 3): 904－ 910. DOI: 10.1016/j.bbrc.2018.01.127.
[7]	CHEN HY, CHEN ZX, HUANG RF, et al. Hepatitis B virus X protein activates human hepatic stellate cells through upregulating TGFβ1[J]. Genet Mol Res, 2014, 13( 4): 8645－ 8656. DOI: 10.4238/2014.October.27.4.
[8]	QIU H, LIN DY, LI JY. Screening and identification of dominant monoclonal HepG2 cell strain with 1.3－fold HBV genome[J]. World Chin J Dig, 2021, 29( 16): 934－ 944. DOI: 10.11569/wcjd.v29.i16.934. 邱华, 林栋毅, 李锦源. HBV 1.3倍基因组HepG2稳转细胞模型优势单克隆株的筛选及鉴定[J]. 世界华人消化杂志, 2021, 29( 16): 934－ 944. DOI: 10.11569/wcjd.v29.i16.934.
[9]	National Health Commission. China health year book 2019[M]. Beijing: Peking Union Medical College Press, 2019. 国家卫生健康委员会. 2019 中国卫生健康统计年鉴[M]. 北京: 中国协和医科大学出版社, 2019.
[10]	ROCKEY DC. Liver fibrosis reversion after suppression of hepatitis B virus[J]. Clin Liver Dis, 2016, 20( 4): 667－ 679. DOI: 10.1016/j.cld.2016.06.003.
[11]	CHANG TT, LIAW YF, WU SS, et al. Long－term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52( 3): 886－ 893. DOI: 10.1002/hep.23785.
[12]	TZIOMALOS K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. World J Hepatol, 2010, 2( 3): 91－ 93. DOI: 10.4254/wjh.v2.i3.91.
[13]	CHEN BW, ZHU XJ, ZHANG X, et al. Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37( 8): 1811－ 1816. DOI: 10.3969/j.issn.1001－5256.2021.08.014. 陈博武, 朱晓骏, 张鑫, 等. 病毒学应答状态对代偿期乙型肝炎肝硬化患者疾病进展的影响[J]. 临床肝胆病杂志, 2021, 37( 8): 1811－ 1816. DOI: 10.3969/j.issn.1001－5256.2021.08.014.
[14]	GIERSCH K, ALLWEISS L, VOLZ T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66( 2): 460－ 462. DOI: 10.1016/j.jhep.2016.09.028.
[15]	MOHAMMADI A, TAJIK N, SHAH－HOSSEINI A, et al. FAS and FAS－ligand promoter polymorphisms in hepatitis B virus infection[J]. Hepat Mon, 2015, 15( 10): e26490. DOI: 10.5812/hepatmon.26490.
[16]	KONDO Y, KOBAYASHI K, ASABE S, et al. Vigorous response of cytotoxic T lymphocytes associated with systemic activation of CD8 T lymphocytes in fulminant hepatitis B[J]. Liver Int, 2004, 24( 6): 561－ 567. DOI: 10.1111/j.1478－3231.2004.0982.x.
[17]	HAQUE M, LEI F, XIONG X, et al. Stem cell－derived viral antigen－specific T cells suppress HBV replication through production of IFN－γ and TNF－α[J]. iScience, 2020, 23( 7): 101333. DOI: 10.1016/j.isci.2020.101333.
[18]	MOON B, CHANG S. Exosome as a delivery vehicle for cancer therapy[J]. Cells, 2022, 11( 3): 316. DOI: 10.3390/cells11030316.
[19]	COCUCCI E, MELDOLESI J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles[J]. Trends Cell Biol, 2015, 25( 6): 364－ 372. DOI: 10.1016/j.tcb.2015.01.004.
[20]	JIA Y, LI Y, WANG YJ. Research progress on exosome targeted delivery of nucleic acid molecules[J]. China Med Herald, 2023, 20( 3): 33－ 36, 49. DOI: 10.20047/j.issn1673－7210.2023.03.07. 贾岳, 李妍, 王英骥. 外泌体靶向递送核酸类分子研究进展[J]. 中国医药导报, 2023, 20( 3): 33－ 36, 49. DOI: 10.20047/j.issn1673－7210.2023.03.07.
[21]	SUN JS, LU MY. Research progress on the formation of exosomes and their rolesin immune regulation[J]. J Tianjin Normal University(Natural Science Edition), 2020, 40( 1): 9－ 15. DOI: 10.19638/j.issn1671－1114.20200102. 孙金生, 陆美伊. 外泌体形成及在免疫调节中的作用研究进展[J]. 天津师范大学学报(自然科学版), 2020, 40( 1): 9－ 15. DOI: 10.19638/j.issn1671－1114.20200102.
[22]	YANG F, YANG T, ZHOU WJ, et al. Macrophage－derived exosomes inhibit HBV DNA replication[J]. Infect Dis Info, 2018, 31( 2): 125－ 130. DOI: 10.3969/j.issn.1007－8134.2018.02.008. 杨帆, 杨涛, 周文靖, 等. 巨噬细胞外泌体抑制HBV DNA复制[J]. 传染病信息, 2018, 31( 2): 125－ 130. DOI: 10.3969/j.issn.1007－8134.2018.02.008.
[23]	ABDULKARIM AS, CAO H, HUANG B, et al. The large GTPase dynamin is required for hepatitis B virus protein secretion from hepatocytes[J]. J Hepatol, 2003, 38( 1): 76－ 83. DOI: 10.1016/s0168－8278(02)00326－4.

Relative Articles

[1]	Jun GAO, Huan CHEN, Yan LIU, Feng ZHANG, Yuzheng ZHUGE. Effect of interleukin-22 on hepatic stellate cell activation and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2229-2237. doi: 10.12449/JCH241116
[2]	Zhiyi WANG, Guangyue YANG, Wei ZHANG, Yaqiong PU, Xin ZHAO, Wenting MA, Xuling LIU, Liu WU, Le TAO, Cheng LIU. Role of podoplanin in hepatic stellate cell activation and liver fibrosis[J]. Journal of Clinical Hepatology, 2024, 40(3): 533-538. doi: 10.12449/JCH240316
[3]	Wentao XIE, Kangkang YU, Qi CHENG, Ning LI. Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B[J]. Journal of Clinical Hepatology, 2023, 39(12): 2845-2850. doi: 10.3969/j.issn.1001-5256.2023.12.015
[4]	Yuxin YAN, Xiaoyang GAO, Chunyan ZHANG, Rong JIN, Hongwei YUAN, Yuehong MA. Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2023, 39(6): 1351-1357. doi: 10.3969/j.issn.1001-5256.2023.06.015
[5]	Jing PENG, Wei YUAN, Sihan YIN, Kewei SUN. Mechanism of NLRP3 inflammasome promoting hepatic stellate cell activation[J]. Journal of Clinical Hepatology, 2022, 38(11): 2611-2615. doi: 10.3969/j.issn.1001-5256.2022.11.035
[6]	Ning YANG, Jiang DENG, Yikai WANG, Sha CHANG, Ning GAO, Wenjun WANG, Shuangsuo DANG, Juanjuan SHI. Role and mechanism of caffeic acid phenethyl ester in hepatic stellate cell[J]. Journal of Clinical Hepatology, 2022, 38(10): 2273-2278. doi: 10.3969/j.issn.1001-5256.2022.10.014
[7]	Tingyu REN, Hezhongrong NIE, Lijia XIAO, Fangnan LIN, Daming WANG, Chunli SONG, Yiwen ZHOU. Effect of hepatitis B x gene-overexpressed hepatocytes on the proliferation and activation of hepatic stellate cells and related mechanism[J]. Journal of Clinical Hepatology, 2021, 37(7): 1561-1566. doi: 10.3969/j.issn.1001-5256.2021.07.017
[8]	Yao YunTing, Zhou YuanZhong, Liu Jun. Role of exosomes in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2333-2339. doi: 10.3969/j.issn.1001-5256.2020.10.038
[9]	Yang MiaoMiao, Wu ZhiHui, Tu ZhengKun. Hepatitis B virus-mediated interaction between hepatic stellate cells and innate immune cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 891-894. doi: 10.3969/j.issn.1001-5256.2020.04.040
[10]	Huang XiaoLi, Liu YingYing, Cong Min. Research advances in drug carrier systems targeting hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(1): 208-212. doi: 10.3969/j.issn.1001-5256.2020.01.050
[11]	Li TianYang, Tu ZhengKun, Su LiShan. Regulatory effect of natural killer cells on hepatic stellate cells and their role in liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 558-562. doi: 10.3969/j.issn.1001-5256.2017.03.036
[12]	Zhao WeiHua, Wang YanHong, Cong Min. Regulatory effect of transforming growth factor-β on activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2195-2198. doi: 10.3969/j.issn.1001-5256.2016.11.044
[13]	Ren ChangZhen, Hao LiSen. Signal transduction involved in activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2015, 31(3): 452-456. doi: 10.3969/j.issn.1001-5256.2015.03.034
[14]	Zhang Zhan, Ping Jian, Xu LieMing. Screening Chinese medicine components for inhibition of human hepatic stellate cell migration[J]. Journal of Clinical Hepatology, 2012, 28(3): 183-188+191.
[15]	Weng ShanGeng, Xu ChangGuo, Sun Ying, Shi Zheng, Lin LiJuan. Study on the apoptosis of rat hepatic stellate cells induced by kapamycin[J]. Journal of Clinical Hepatology, 2012, 28(3): 219-222.
[16]	Lu XiaoJu, Chen YongPing, Yang Tao, Cheng Yuan, Jin XiaoZhi, Shen ChunYan, Liu Jun, Wang ChunYing, Wang XiaoDong, Lin Zhuo. The influence of regulatory T cells in hepatic stellate cell proliferation and HA secretion[J]. Journal of Clinical Hepatology, 2012, 28(1): 39-43.
[17]	Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979.
[18]	Dai YongMei, Cai LiMian, Lin Leng. The effect of octreotide on the expression of collagen、TIMP-1 and MMP-2 in HSC1[J]. Journal of Clinical Hepatology, 2008, 24(5): 332-334.
[19]	Yang WeiFeng, Chen HouChang, Li Lin. Effect of Curcumin on proliferation and extracellular matrix secretion of rat hepatic stellate cells in vitro[J]. Journal of Clinical Hepatology, 2004, 20(3): 142-143.
[20]	Cheng JiLin, Zhou Xin, Li DingGuo, Wei HongShan, Huang Xin, Wang ZhiRong, Zhan YuTao, Zhang Jing, Xu QinFang, Lu HanMing. RGDS peptides inhibit hepatic stellate cells synthesizing extracellular matrix stimulated by transforming growth factor beta.[J]. Journal of Clinical Hepatology, 2001, 17(3): 173-175.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 李晶津，王佳玉，金泽宁. 昼夜节律对肝脏胆固醇代谢的影响. 中西医结合肝病杂志. 2022(12): 1110-1113 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (453) PDF downloads(44)

Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation

DOI: 10.3969/j.issn.1001-5256.2023.10.011

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation

DOI: 10.3969/j.issn.1001-5256.2023.10.011

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content